Cisplatin-induced threshold shift in the CBA/CaJ, C57BL/6J, BALB/cJ mouse models of hearing loss

DeBacker, J. Riley; Harrison, Ryan T.; Bielefeld, Eric C.

doi:10.1016/j.heares.2019.107878

Cited by 19 publications

(11 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although ABR values did not show a significant difference, the female cisplatin group had more apoptotic spiral ganglion neurons [ 77 ]. One recent study reported that inconsistent hearing thresholds after cisplatin injection were observed in different strains of mice [ 78 ]. For example, the CBA/CaJ mice revealed no significant sex difference; the female C57BL/6J mice had higher threshold shifts than the males at 4 kHz and 16 kHz.…”

Section: Animal Investigations Of Sex Differences In Acquired Sensorineural Hearing Lossmentioning

confidence: 99%

Sex Differences in the Triad of Acquired Sensorineural Hearing Loss

Lien

Yang

2021

IJMS

View full text Add to dashboard Cite

The triad of noise-generated, drug-induced, and age-related hearing loss is the major cause of acquired sensorineural hearing loss (ASNHL) in modern society. Although these three forms of hearing loss display similar underlying mechanisms, detailed studies have revealed the presence of sex differences in the auditory system both in human and animal models of ASNHL. However, the sexual dimorphism of hearing varies among noise-induced hearing loss (NIHL), ototoxicity, and age-related hearing loss (ARHL). Importantly, estrogen may play an essential role in modulating the pathophysiological mechanisms in the cochlea and several reports have shown that the effects of hormone replacement therapy on hearing loss are complex. This review will summarize the clinical features of sex differences in ASNHL, compare the animal investigations of cochlear sexual dimorphism in response to the three insults, and address how estrogen affects the auditory organ at molecular levels.

show abstract

Section: Animal Investigations Of Sex Differences In Acquired Sensorineural Hearing Lossmentioning

confidence: 99%

Sex Differences in the Triad of Acquired Sensorineural Hearing Loss

Lien

Yang

2021

IJMS

View full text Add to dashboard Cite

show abstract

“…Studies demonstrated that a single intraperitoneal dose (commonly 12-16 mg/kg) of cisplatin in rats, mice, or guinea pigs could cause timedependent damage of OHCs and the stria vascularis (Table 2) (56)(57)(58)(59)(60). Some studies also adopted regimens of lower single-dose multiple-administrations which resulted in low mortality rates (69). Death rates were lower in CBA/CaJ mice and C57BL/6J mice exposed to 48 mg/kg cisplatin and (69).…”

Section: Platinum Antitumor Drugsmentioning

confidence: 99%

“…Some studies also adopted regimens of lower single-dose multiple-administrations which resulted in low mortality rates (69). Death rates were lower in CBA/CaJ mice and C57BL/6J mice exposed to 48 mg/kg cisplatin and (69). Furthermore, the susceptibility to cisplatin ototoxicity in rats and mice can be affected by their circadian times, where the highest ABR threshold shift and the most severe OHC loss occur in the middle of the light circle (70,71).…”

Section: Platinum Antitumor Drugsmentioning

confidence: 99%

Experimental animal models of drug-induced sensorineural hearing loss: a narrative review

Lin¹,

Luo²,

Tan

et al. 2021

Ann Transl Med

View full text Add to dashboard Cite

This narrative review describes experimental animal models of sensorineural hearing loss (SNHL) caused by ototoxic agents.Background: SNHL primarily results from damage to the sensory organ within the inner ear or the vestibulocochlear nerve (cranial nerve VIII). The main etiology of SNHL includes genetic diseases, presbycusis, ototoxic agents, infection, and noise exposure. Animal models with functional and anatomic damage to the sensory organ within the inner ear or the vestibulocochlear nerve mimicking the damage seen in humans are employed to explore the mechanism and potential treatment of SNHL. These animal models of SNHL are commonly established using ototoxic agents.Methods: A literature search of PubMed, Embase, and Web of Science was performed for research articles on hearing loss and ototoxic agents in animal models of hearing loss.Conclusions: Common ototoxic medications such as aminoglycoside antibiotics (AABs) and platinum antitumor drugs are extensively used to induce SNHL in experimental animals. The effect of ototoxic agents in vivo is influenced by the chemical mechanisms of the ototoxic agents, the species of animal, routes of administration of the ototoxic agents, and the dosage of ototoxic agents. Animal models of drug-induced SNHL contribute to understanding the hearing mechanism and reveal the function of different parts of the auditory system in humans.

show abstract

“…For example, guinea pigs exhibit an increased sensitivity to cisplatin compared with mice (Poirrier et al, 2010). Among different mouse strains (CBA/CaJ, C57BL/6J, BALB/cJ mouse), the BALB/cJ strain had the greatest threshold shift after cisplatin injection and the lowest mortality (DeBacker et al, 2020). It suggests the need for careful selection of animal species.…”

Section: Intraperitoneal Injection (Single/multi-dose)mentioning

confidence: 99%

Current Strategies to Combat Cisplatin-Induced Ototoxicity

Chen

et al. 2020

Front. Pharmacol.

View full text Add to dashboard Cite

Cisplatin is widely used for the treatment of a number of solid malignant tumors. However, ototoxicity induced by cisplatin is an obstacle to effective treatment of tumors. The basis for this toxicity has not been fully elucidated. It is generally accepted that hearing loss is due to excessive production of reactive oxygen species by cells of the cochlea. In addition, recent data suggest that inflammation may trigger inner ear cell death through endoplasmic reticulum stress, autophagy, and necroptosis, which induce apoptosis. Strategies have been extensively explored by which to prevent, alleviate, and treat cisplatin-induced ototoxicity, which minimize interference with antitumor activity. Of these strategies, none have been approved by the Federal Drug Administration, although several preclinical studies have been promising. This review highlights recent strategies that reduce cisplatin-induced ototoxicity. The focus of this review is to identify candidate agents as novel molecular targets, drug administration routes, delivery systems, and dosage schedules. Animal models of cisplatin ototoxicity are described that have been used to evaluate drug efficacy and side effect prevention. Finally, clinical reports of otoprotection in patients treated with cisplatin are highlighted. For the future, high-quality studies are required to provide reliable data regarding the safety and effectiveness of pharmacological interventions that reduce cisplatin-induced ototoxicity.

show abstract

Cisplatin-induced threshold shift in the CBA/CaJ, C57BL/6J, BALB/cJ mouse models of hearing loss

Cited by 19 publications

References 53 publications

Sex Differences in the Triad of Acquired Sensorineural Hearing Loss

Sex Differences in the Triad of Acquired Sensorineural Hearing Loss

Experimental animal models of drug-induced sensorineural hearing loss: a narrative review

Current Strategies to Combat Cisplatin-Induced Ototoxicity

Contact Info

Product

Resources

About